Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the challenges presented by patients with high-risk (HR) multiple myeloma and comments on an ongoing analysis which aims to improve outcomes for these patients. Dr Usmani also highlights the increased use of an enrichment approach in clinical trials in this disease setting. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть